CVC  BrightEdge Ventures

https://www.cancer.org/involved/donate/bright edge.html





     Office Locations:

250 Williams Street NW
Atlanta, GA 30303
Phone: 800-227-2345

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    BrightEdge is the Philanthropic Impact Fund of the American Cancer Society (ACS). The firm's goal is to invest in companies that accelerate access to lifesaving technologies for the patients and families ACS serves. BrightEdge will accelerate the ACS mission while creating a sustainable funding source into the next century. BrightEdge raises capital from Impact Donors who want to have a more direct approach to philanthropy. BrightEdge invests in for-profit companies and its goal is to advance the speed of commercial adoption of novel and innovative therapies, diagnostics, devices, and technologies.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Bob Crutchfield Managing Director
    Gary Reedy CEO
    Mike Krepps Principal

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      09/29/2021


      TailorMed


      NY


      $25,000,000


      


      08/18/2021


      Immunitas Therapeutics


      MA


      $58,000,000


      Series B


     

    Portfolio companies include:

     

    Recent News: